225,242]. The successful development of mRNA-based COVID-19 vaccines has opened up exciting new opportunities for novel mRNA-based drugs and vaccines to combat a variety of challenging diseases. Some of the most promising applications
225,242]. The successful development of mRNA-based COVID-19 vaccines has opened up exciting new opportunities for novel mRNA-based drugs and vaccines to combat a variety of challenging diseases. Some of the most promising applications
Antibody technology is widely used in the fields of biomedical and clinical therapies. Nonetheless, the complex in vitro expression of recombinant proteins, long production cycles, and harsh storage conditions have limited their applications in medicine, especially in clinical therapies. Recently, this di...
Amino Acids 2007; 32: 101–108. 58 Wassell J. Haptoglobin: function and polymorphism. Clin Lab 2000; 46: 547–552. 59 Asleh R, Marsh S, Shilkrut M, Binah O, Guetta J, Lejbkowicz F et al. Genetically determined heterogeneity in hemoglobin scavenging and susceptibility to dia- betic ...
Realizing the immense clinical potential of mRNA-based drugs will require continued development of methods to safely deliver the bioactive agents with high efficiency and without triggering side effects. In this regard, lipid nanoparticles have been succ
strings together amino acids in the order specified by the sequence of elements in the mRNA molecule. Since the (10) amount of mRNA in a cell determines the amount of the corresponding protein, factors affecting the abundance of mRNA’s play a major part in the normal functioning of a cell...
Lipid nanoparticle-assisted mRNA inhalation therapy necessitates addressing challenges such as resistance to shear force damage, mucus penetration, cellular internalization, rapid lysosomal escape, and target protein expression. Here, we introduce the in
These antigens are common, but have low tumor specificity and are subject to central tolerance, thus limiting their immunogenicity. Cancer testis anti- gens (CTAs) are another category of TAAs, which usually over expressed in a variety of cancers, as well as normally expressed in the normal ...
In the CGD patients with mutations in this PU.1 binding site, CYBB mRNA was less than 10% of normal, suggesting that PU.1 may bind to one or more additional, more distal cis elements. In a Jurkat T-cell line, the same luciferase reporter construct was only active when also PU.1 was...
(a) check for sign of visible adverse reaction of administration before and after injection, (b) HE stained tissue from site of injection for erythema and edema, (c) WBC, white blood count, (d) RBC, red blood cell, (e) HGB, hemoglobin, (f) MCV, mean corpuscular volume, (g) MCH,...